Your Position:Home>Products>Monoclonals/Polyclonals>Anti-Human CCL2/JE/MCP-1 Reference Antibody

Anti-Human CCL2/JE/MCP-1 Reference Antibody

  • Cat. No.:RB9THY280016
  • Price:Negotiable
  • Clicks:352

Product Detail

Product Parameters

FormLiquid
Host SpeciesHuman
ClonalityMonoclonal
IsotypeIgG1-kappa
Purity>95% as determined by SDS-PAGE.
PurificationProtein A/G purified from cell culture supernatant.
Concentration2.08 mg/ml
Endotoxin LevelPlease contact with the lab for this information.
ApplicationsELISA, Bioactivity: FACS, Functional assay, Research in vivo
Species ReactivityHuman
TargetHC11, MCP-1, MCP1, Monocyte chemotactic protein 1, Monocyte chemotactic and activating factor, Small-inducible cytokine A2, SCYA2, MCAF, Monocyte secretory protein JE, C-C motif chemokine 2, Monocyte
Storage Buffer0.01M PBS, pH 7.4.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Expression SystemMammalian Cells
Accession NumberP13500
BackgroundCarlumab, developed by Janssen Biotech, is a recombinant human IgG1 monoclonal antibody targeting CC chemokine ligand 2 (CCL2). The recombinant protein has been developed for the treatment of cancer and prostate cancer, and has also been studied in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis, and type 2 diabetes. In the beginning, phage display technology was used to confirm the high affinity between Carlumab and CCL2, which provided a basis for future clinical trials. In 2013, Carlumab was used to treat metastatic castrated prostate cancer and solid tumors. The anti-tumor activity of Carlumab was preliminarily determined through the study of its safety, tolerance, pharmacokinetics-pharmacodynamics and anti-tumor activity. Subsequently, some studies have evaluated the safety and efficacy of Carlumab in the treatment of (IPF) with idiopathic pulmonary fibrosis, but the results are not satisfactory. Due to the limited success rate of clinical trials, carlumab was discontinued in 2012.
• MCP-1 gene (SCYA2) and schizophrenia: a case-control association study., PMID:15389752
• The MCP-1 gene (SCYA2) and mood disorders: preliminary results of a case-control association study., PMID:19923858
Alternative NamesCNTO 888, 915404-94-3
SpeciesHuman
NoteFor research use only. Not suitable for clinical or therapeutic use.
For Research Use Only. Not for Diagnostic Procedures.

Related Products:
Total 33055 records,Divided into 1653 pages,The 1 pages | First Prev Next Last
Live Chat
  • Tel:
  • WeChat ID: 15898894496
  • Add Message
  • 9:00 AM – 6:00 PM